PET imaging firm CellSight Technologies is collaborating with Boehringer Ingelheim to evaluate its VisAcT PET imaging tracer for future use in the development and monitoring of immune-oncological therapies.
VisAcT is designed for uptake by activated T cells, which would noninvasively determine changes in T-cell activation within tumor lesions. A clinical trial is currently underway to evaluate immunological response to activation within the body's anticancer immune system for squamous cell carcinoma of the head and neck.
The goal is to determine if PET scans at six and 12 weeks after the initial anti-inhibitor therapy dose with the VisAcT tracer are predictive of response to immunotherapy, the company said.
The researchers are recruiting 20 subjects for the trial at the Stanford University Medical Center.
